CaseyCasey Quinn Quinn, PhD

Health Economics and Financing Research Lead, FoCUS Program

Casey Quinn, PhD, is the Health Economics and Financing Research Lead in the Center for Biomedical Innovation/NEWDIGS Financing and Reimbursement of Cures in the US (FoCUS) program. Dr Quinn is responsible for supporting the gene therapies, oncology, and antibiotics teams with research into biopharmaceutical assets, helping teams to develop case studies and financing and reimbursement toolkits for the design labs. He will also lead the research and systems modeling/simulation for the pilot projects.

Dr Quinn’s previous experience includes payer and commissioning roles with the UK NICE, NIHR, and NHS funding committees. In FoCUS, he is taking a role that spans general health economics and modeling methodology, as well as evidence generation from a payer perspective and how that feeds into measuring, valuing and financing innovation in new therapies.

An econometrician and health economist, Dr Quinn is experienced in survival modeling, economic modeling and cost-effectiveness analysis, as well as outcomes measurement and economic evaluation more generally. Dr Quinn’s career includes academic teaching and research, and industry consulting. His disease knowledge spans oncology and gene therapies (solid and hematological malignancies, including orphan diseases), respiratory, skin, CNS, and musculoskeletal disease, and behavioral disorders.

Currently Dr Quinn is also Director of Health Economics and Outcomes Research (HEOR) in a UK-based pricing, reimbursement, and market access consulting firm. Since 2011 he has worked on supporting Health Technology Assessment (HTA) globally, reimbursement submission and value dossiers, core economic modeling, indirect & mixed treatment comparisons, utility studies, costing studies, budget impact modeling, and estimating burden of illness.

He earned his PhD in Health Economics from the University of York and has taught economics, health economics, and statistics at universities in Australia, the UK, and the US.